Work

Cost-effectiveness and safety comparison of tremelimumab-durvalumab (STRIDE) versus atezolizumab-bevacizumab in unresectable hepatocellular carcinoma.

Year: 2025

Type: conference-abstract

Source: JCO Oncology Practice

DOI: 10.1200/op.2025.21.10_suppl.6

Authors: Maha Zafar, Manaswini Krishnakumar, Aswanth Reddy

Institution: Arkansas Colleges of Health Education

Language: English

Topic: Hepatocellular Carcinoma Treatment and Prognosis

Subfield: Hepatology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4414893185

Cites:

Cited by:

Related to: